Online Only Articles

Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab

Department of Hematology, Amsterdam University Medical Centers, Location AMC, Amsterdam, on behalf of Hovon CLL Working Group, Amsterdam, the Netherlands
Genentech, Inc., South San Francisco, CA, USA
AbbVie, North Chicago, IL, USA
Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
Vol. 105 No. 7 (2020): July, 2020